Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. BIIB has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
BIIB stock price ended at $129.47 on Monday, after rising3.09%
The Biogen Inc stock price increased by 3.09% on the last trading day (19 May 2025), rising from 126.05 to 129.47. Throughout the last trading session, the stock experienced a fluctuation of 3.70% , ranging from a day low of $124.93 to a day high of 129.55. The price has declined in 4 of the last 10 days, resulting in a total change of 6.30% during this period. On the last day, trading volume decrease by 535.45K shares, with the rising prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 2.34M shares were traded, amounting to approximately 298.44M.
BIIB Technical Signals
BIIB(Biogen Inc Corp) has 3 buy signals and 4 sell signals now. The current trend is downtrend starting from 2025-05-01. The total price change during this trend is +3.85%. Recently, the price has increased but the volume has decreased, indicating a potential warning signal. The average turnover of BIIB over the last 5 trading days is 235.23M. Overall, the technical indicator signals lean more toward a Neutral outlook in the mid-term.
BIIB Moving Average Analysis
Biogen Inc's overall moving average trend leans more bullish as of Tuesday, May 20, 2025, with 2 negative signals and 2 positive signal. In the mid-term, the SMA_20 being below the SMA_60 signals a strong bearish trend. There will be some resistance from the lines at $127.16169333333332, and $131.18033333333332. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $114.15897333333334, and $110.14033333333333. A break-down below any of these levels will issue sell signals.
BIIB Short Selling Analysis
The short sale ratio of Biogen Inc(BIIB) as of 12 May 2025 is 8.43%, dropping from last trading day. With decreasing price from 118.17 to 124.40. The short sell activity indicate that short sellers may be experiencing short cover.
Technical Signal
Technical Signals Summary
Sell
4
Buy
3
Moving Average
Swing
Positive
Stock Price Above SMA_5
Short Term
Positive
SMA_5 Above SMA_20
Mid Term
Negative
SMA_20 Below SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
3 Bullish Signals
3 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Awesome Oscillator (5, 34)
AO_5_34 > 0
1.539
Bullish
Momentum (10 days)
MOM_10 > 0
2.06
Bullish
Closing price
close > fibonacci_R1
125.59
Bullish
4 Bearish Signals
4 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Commodity Channel Index (20 days, 0.015 constant)
CCI_20_0.015 > 100
151.707
Bearish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 < 0
-0.683
Bearish
Stochastic RSI %K (14, 14, 3, 3)
STOCHRSIk_14_14_3_3 > 80
81.189
Bearish
Williams %R (14 days)
WILLR_14 > -20
-1.711
Bearish
BIIB Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Biogen Inc(BIIB), our algorithm predicts BIIB's 1-month price at $109.83, with an -7.06%downwardshift. Using a similarity score up to 96.13%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Biogen Inc (BIIB.O) stock, as of Sunday, May 11, 2025 , forecasts a -7.06% change over the next month, based on its high correlation with KKR.N stock patterns. The similarity between their price movements over the analyzed periods is 96.13%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
BIIB
No Data
KKR
Down: -7.06%Similarity: 96.13%
Name
Similarity
Up/Down
KKR.N
96.13%
-7.06%
MTEX.O
96.02%
+3.24%
BFAM.N
95.98%
+4.18%
TIMB.N
95.85%
+2.70%
AGO.N
95.76%
+4.06%
DSY.O
95.65%
-44.16%
ELDN.O
95.62%
+2.41%
FEDU.N
95.59%
+23.60%
HDSN.O
95.58%
+39.17%
KREF.N
95.56%
+1.63%
BIIB Seasonality Analysis
Based on BIIB's historical stock price data across all years, the probability of a positive return in May is63.64%, suggesting it maybe an ideal month to invest in BIIB. In contrast,Mayoffers the highest probability of positive returns at63.64%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Biogen Inc (BIIB.O) stock in May has the highest probability of a positive return (63.64%), while April has the lowest probability (18.18%).
Performance Seasonality
The chart shows Biogen Inc. (BIIB)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
People Also Watch
FAQ
Should I buy Biogen Inc (BIIB.O) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. BIIB has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
Which months have the highest win rate for buying Biogen Inc (BIIB.O) stock in a year?
The radar chart shows that buying Biogen Inc (BIIB.O) stock in May has the highest probability of a positive return (63.64%), while April has the lowest probability (18.18%).
How has Biogen Inc. (BIIB)'s stock price performed over the past three years?
BIIB's stock price fell by -5.08% in 2023,decreased by -42.88% in 2024, and went down by 13.69% in 2025.
Which bull technical signals does BIIB have?
Bullish technical signals of BIIB include: AO_5_34 > 0, MOM_10 > 0, close > fibonacci_R1.
Is BIIB a buy based on overall technical signals summary?
BIIB has 3 buy signals and 4 sell signals now. Overall the technical rating for BIIB is Neutral . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of BIIB.
What is the trend of Biogen Inc (BIIB)'s moving average?
Biogen Inc's overall moving average trend leans more bullish as of May 20 2025, with 2 negative signals and 2 positive signal.
What is price prediction for BIIB stock next month?
The price prediction chart for Biogen Inc (BIIB.O) stock, as of May 11 2025, forecasts a -7.06% change over the next month, based on its high correlation with KKR stock patterns. The similarity between their price movements over the analyzed periods is 96.13%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for BIIB Stock?
BIIB stock is predicted to reach **$135** in 2025. This forecast is based on analyst price targets and technical analysis, with the stock facing resistance and needing consolidation.
What is price prediction 2030 for BIIB Stock?
### **Price Prediction for BIIB Stock by 2030**
BIIB stock is predicted to reach **$190 - $200** by 2030, driven by strong growth from its Alzheimer's drug Leqembi and other neurological treatments.
**Reasons:**
- **Product Growth**: Leqembi and Skyclarys are expected to boost long-term revenue.
- **Pipeline Strength**: BIIB's focus on neurological and neurodegenerative diseases positions it for sustained growth.
- **Analyst Targets**: The average 12-month target is $190.79, with a high of $265.